

## **Patient Advocacy Group Input**

June 4, 2012

Hello,

Patient input on drug reviews and feedback on recommendations is important to the pCODR drug review process as it ensures that patients' experiences of living with cancer and undergoing treatment are routinely considered as part of the pCODR drug review process. In particular, patient input means that those reviewing the drug can begin to appreciate the impact (both good and bad) that the drug under review may have on those taking it, as well as on those caring for patients living with cancer.

Last July pCODR began accepting submissions. We worked with a number of stakeholders, including patient advocacy groups, to help shape the pCODR review process, guidelines and templates. One of pCODR's guiding principles is ongoing evaluation. We have received positive feedback relating to the content and questions posed in the pCODR Patient Advocacy Group Input on a Drug Review template. We will continue to explore concrete and collaborative ways to ensure patient advocacy group input is most useful to the review process and makes the best possible representation of patient and caregiver evidence.

We also have received feedback that the page limit for input has been challenging for some patient advocacy groups. As a result, we have revised the *pCODR Patient Engagement Guide* and the *pCODR Patient Advocacy Group Input on a Drug Review* template to permit more space for input.

The revised pCODR Patient Advocacy Group Input on a Drug Review template allows for:

- Eight (8) typed 8 ½" by 11" pages
- · The deletion of instructions, questions and examples under each heading

The revised pCODR Patient Engagement Guide and pCODR Patient Advocacy Group Input on a Drug Review template are now available on the pCODR website (under Step 3.2 of Our Review Process). The newly revised pCODR Patient Advocacy Group Input on a Drug Review template may be used for any submission received on or after June 4, 2012.

The contributions of patient advocacy groups have been invaluable in shaping the pCODR process. As always, the pCODR secretariat welcomes feedback from those involved in the process. If you should have any questions please contact <a href="mailto:info@pcodr.ca">info@pcodr.ca</a>.

Sincerely,

Mona Sabharwal Executive Director

m. luhl